APA (7th ed.) Citation

Yang, Y., Mortazavi, A., Presley, C., Konda, B., Backes, F., Mittra, A., . . . Li, M. (2025). 2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial. Annals of Oncology, 36, S1538. https://doi.org/10.1016/j.annonc.2025.08.3548

Chicago Style (17th ed.) Citation

Yang, Y.A, et al. "2936eP Immune Checkpoint Inhibitor Rechallenge in Combination with Siltuximab Prophylaxis for Patients Who Had Prior Immune-related Adverse Event: Preliminary Safety Results from the Phase 2 CIRES Trial." Annals of Oncology 36 (2025): S1538. https://doi.org/10.1016/j.annonc.2025.08.3548.

MLA (9th ed.) Citation

Yang, Y.A, et al. "2936eP Immune Checkpoint Inhibitor Rechallenge in Combination with Siltuximab Prophylaxis for Patients Who Had Prior Immune-related Adverse Event: Preliminary Safety Results from the Phase 2 CIRES Trial." Annals of Oncology, vol. 36, 2025, p. S1538, https://doi.org/10.1016/j.annonc.2025.08.3548.